Dual Responsive Magnetic DCR3 Nanoparticles: A New Strategy for Efficiently Targeting Hepatocellular Carcinoma
Small · 2025
DOI: 10.1002/smll.202402909 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2025. Verfasst von Lina Jia und 11 weiteren Autor:innen. Beteiligte Einrichtung: College of Information and Engineering, Hebei GEO University, Shijiazhuang, 050031, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Receptors, Tumor Necrosis Factor, Member 6b, Nanoparticles. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Beijing Municipal Fund for Distinguished Young Scholars, National Key R&D Program of China, Beijing Natural Science Foundation.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is a major cause of cancer deaths globally. Unlike traditional molecularly targeted drugs, magnetically controlled drug delivery to micro/nanorobots enhances precision in targeting tumors, improving drug efficiency and minimizing side effects. This study develops a dual‐responsive, magnetically controlled drug delivery system using PEGylated paramagnetic nanoparticles conjugated with decoy receptor 3 (DCR3) antibodies. The clusters demonstrate capabilities for long‐range, magnetically driven control and molecular chemotaxis. Paramagnetic PEGylated particles form vortex‐ and liquid‐like drug moieties within a magnetically controlled system. Vortex‐like nanoparticle clusters exhibit high controllability and countercurrent movement, while liquid‐nanoparticle robot clusters display greater deformability. Upon loading with DCR3 antibodies, the particles navigate along DCR3‐protein gradients in blood and tissue, effectively targeting liver tumor sites in vivo. Clusters of DCR3‐coupled magnetic nanoparticles target cells that highly express DCR3, thereby effectively inhibiting tumor cell proliferation and migration. Compared with conventional nanomedicine, DCR3‐coupled magnetic nanoparticle clusters are capable of delivering controlled drugs over long distances and responding in a molecular‐targeting manner. This research is expected to significantly impact the field of precise tumor drug delivery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Information and Engineering, Hebei GEO University, Shijiazhuang, 050031, China.
- Intelligent Sensor Network Engineering Research Center of Hebei Province, Shijiazhuang, 050031, China.
- Department of Mechanical Engineering, The University of Tokyo, Tokyo, Japan, 113-8656.
- Department of General Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, China.
- School of Mechanical Engineering and Automation, Beihang University, Beijing, 100191, China.
- Beijing Sinogene Biotechnology Co. Ltd, Beijing, 100005, China.
ORCID-Profile: Lin Feng
Förderung
- Beijing Municipal Fund for Distinguished Young Scholars
- National Key R&D Program of China
- Beijing Natural Science Foundation
- National Key Research and Development Program of China
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
Jia, L., Dai, Y., Xu, Y., Sun, H., Gao, H., Hao, H., Wang, L., Xu, J., Shang, J., Li, G., Xu, Y., & Feng, L. (2025). Dual Responsive Magnetic DCR3 Nanoparticles: A New Strategy for Efficiently Targeting Hepatocellular Carcinoma. Small. https://doi.org/10.1002/smll.202402909
Vancouver
Jia L, Dai Y, Xu Y, Sun H, Gao H, Hao H, et al. Dual Responsive Magnetic DCR3 Nanoparticles: A New Strategy for Efficiently Targeting Hepatocellular Carcinoma. Small. 2025. doi:10.1002/smll.202402909
BibTeX
@article{Jia2025,
author = {Jia, Lina and Dai, Yuguo and Xu, Yingchen and Sun, Hongyan and Gao, Han and Hao, Haiyang and Wang, Luyao and Xu, Junjie and Shang, Juanjuan and Li, Guangming and Xu, Ye and Feng, Lin},
title = {Dual Responsive Magnetic DCR3 Nanoparticles: A New Strategy for Efficiently Targeting Hepatocellular Carcinoma},
journal = {Small},
year = {2025},
doi = {10.1002/smll.202402909}
}
EUVIMED